Pfizer’s Willem Scheele Joins Imara as Chief Medical Officer

Imara has hired Willem Scheele to serve as its as chief medical officer. Before joining the Cambridge, MA, biotech, Scheele was executive director and clinician group lead in rare diseases for Pfizer (NYSE: [[ticker:PFE]]). Scheele’s new role at Imara follows the company’s recent $63 million Series B round of funding. Imara emerged from biotech accelerator Cydan Development in 2016. The company’s lead drug, IMR-687, is in early-stage testing as a treatment for sickle cell disease.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.